Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
DHVD3 may boost IPV responses in humans; leaves open translation from murine models to clinical use.
1,25-Dihydroxyvitamin D3 (DHVD3) coadministered with monovalent inactivated poliovirus vaccine (IPV) of all 3 serotypes significantly enhances antipoliovirus systemic and mucosal immunity in mice. Although serum immunoglobulin G antibodies are significantly higher in serotypes 2 and 3, and although salivary immunoglobulin A is significantly increased in serotypes 1 and 3, DHVD3 had the most dramatic effect on the level of neutralizing serum antibodies of all 3 IPV serotypes. These findings suggest a possible use of vitamin D3 as an adjuvant for currently used and proposed new Sabin IPVs.
No takes yet. Share an insight, caveat, or question.
Ap et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: